No need to submit new authorization requests for Neulasta for HCPCS code J2506

On Jan. 1, 2022, the HCPCS code for Neulasta/Neulasta^® Onpro^® (pegfilgrastim) changed from J2505 to J2506. Health care providers who received an authorization from AIM Specialty Health^® for Neulasta under HCPCS code J2505 don’t need to submit a new authorization request due to the code change. 

Instead, we’ve updated the Blue Cross Blue Shield of Michigan and Blue Care Network e-referral system so that the new HCPCS code J2506 is assigned to existing Neulasta authorizations.

Check the e-referral system to confirm that your authorizations have been updated to HCPCS code 2506. This change may not be reflected in the AIM provider portal.

In the future, submit prior authorization requests for Neulasta as follows:

• For dates of service on or after Jan. 1, 2022, use HCPCS code J2506.
• For dates of service before Jan. 1, 2022, use HCPCS code J2505.

We’ve updated the following drug lists to reflect the code change:

• For commercial members, see:
• Standard commercial medical drug program: Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial (PDF)
• Medical oncology drug program: Medical oncology prior authorization list for Blue Cross and BCN commercial members (PDF)
• For Medicare Advantage members, see the Medical Drug and Step Therapy Prior Authorization List for Medicare Plus BlueSM and BCN AdvantageSM members (PDF)

AIM is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to provide benefit management services.